

# Thomas Fischer

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/11081190/publications.pdf>

Version: 2024-02-01

69  
papers

15,053  
citations

136740

32  
h-index

138251

58  
g-index

71  
all docs

71  
docs citations

71  
times ranked

11103  
citing authors

#	ARTICLE	IF	CITATIONS
1	Molecular landscape and prognostic impact of FLT3-ITD insertion site in acute myeloid leukemia: RATIFY study results. <i>Leukemia</i> , 2022, 36, 90-99.	3.3	42
2	Genetic Knock-out of TNFR1 and TNFR2 in a JAK2-V617F Polycythemia Vera Mouse Model. <i>HemaSphere</i> , 2022, 6, e717.	1.2	0
3	Randomized Trial of a Supportive Psychotherapy for Parents of Adolescents and Young Adults With Hematologic Malignancies. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2022, , 1-15.	2.3	4
4	Directional mast cell degranulation of tumor necrosis factor into blood vessels primes neutrophil extravasation. <i>Immunity</i> , 2021, 54, 468-483.e5.	6.6	56
5	Allogeneic stem cell transplantation for mantle cell lymphoma—update of the prospective trials of the East German Study Group Hematology/Oncology (OSHO#60 and #74). <i>Annals of Hematology</i> , 2021, 100, 1569-1577.	0.8	6
6	Allogeneic hematopoietic stem cell transplantation improves long-term outcome for relapsed AML patients across all ages: results from two East German Study Group Hematology and Oncology (OSHO) trials. <i>Annals of Hematology</i> , 2021, 100, 2387-2398.	0.8	11
7	Low skeletal muscle mass is a predictor of treatment related toxicity in oncologic patients. A meta-analysis. <i>Clinical Nutrition</i> , 2021, 40, 5298-5310.	2.3	30
8	<i>Klebsiella oxytoca</i> causes colonization resistance against multidrug-resistant <i>K. pneumoniae</i> in the gut via cooperative carbohydrate competition. <i>Cell Host and Microbe</i> , 2021, 29, 1663-1679.e7.	5.1	53
9	AXL Inhibition Represents a Novel Therapeutic Approach in Negative Myeloproliferative Neoplasms. <i>HemaSphere</i> , 2021, 5, e630.	1.2	0
10	Dose reduction and high-risk disease as risk factors for early death in primary CNS lymphoma. <i>Leukemia and Lymphoma</i> , 2020, 61, 240-242.	0.6	0
11	Activating JAK-mutations confer resistance to FLT3 kinase inhibitors in FLT3-ITD positive AML in vitro and in vivo. <i>Leukemia</i> , 2020, 35, 2017-2029.	3.3	27
12	Is bendamustine-rituximab a reasonable treatment in selected older patients with diffuse large B cell lymphoma? Results from a multicentre, retrospective study. <i>Annals of Hematology</i> , 2019, 98, 2729-2737.	0.8	9
13	Allogeneic transplantation in multiple myeloma: long-term follow-up and cytogenetic subgroup analysis. <i>Leukemia</i> , 2019, 33, 2710-2719.	3.3	28
14	Targeting RIPK1 in AML cells carrying FLT3-ITD. <i>International Journal of Cancer</i> , 2019, 145, 1558-1569.	2.3	10
15	SDF1-induced chemotaxis of JAK2-V617F-positive cells is dependent on Bruton tyrosine kinase and its downstream targets PI3K/AKT, PLC $\beta$ 1 and RhoA. <i>Haematologica</i> , 2019, 104, e288-e292.	1.7	4
16	Primary ecthyma gangraenosum due to central venous catheter-related bloodstream infection with <i>Pseudomonas aeruginosa</i> . <i>Infection</i> , 2019, 47, 333-334.	2.3	0
17	JAK2-V617F promotes venous thrombosis through $\beta$ 1/ $\beta$ 2 integrin activation. <i>Journal of Clinical Investigation</i> , 2018, 128, 4359-4371.	3.9	88
18	Tyrosine kinase inhibitor-induced defects in DNA repair sensitize FLT3(ITD)-positive leukemia cells to PARP1 inhibitors. <i>Blood</i> , 2018, 132, 67-77.	0.6	54

#	ARTICLE	IF	CITATIONS
19	Therapeutic Potential of Axl Blockade in BCR-ABL Negative Myeloproliferative Neoplasms (MPN). <i>Blood</i> , 2018, 132, 3063-3063.	0.6	0
20	In Vivo Blockade of Beta-1 and Beta-2 Integrin Activity Inhibits Splenomegaly in JAK2-V617F Positive Myeloproliferative Disease. <i>Blood</i> , 2018, 132, 1778-1778.	0.6	0
21	Diagnostic and therapeutic challenges in extragonadal yolk sac tumor with hepatoid differentiation: A case report. <i>Molecular and Clinical Oncology</i> , 2017, 6, 79-82.	0.4	5
22	The multi-site docking protein Gab1 is constitutively phosphorylated independent from its recruitment to the plasma membrane in Jak2-V617F-positive cells and mediates proliferation of human erythroleukaemia cells. <i>Cellular Signalling</i> , 2017, 35, 37-47.	1.7	10
23	Impact of lymphopenia on prognosis of patients with primary central nervous system lymphoma. <i>European Journal of Cancer</i> , 2017, 75, 280-283.	1.3	5
24	Activated protein C protects from GvHD via PAR2/PAR3 signalling in regulatory T-cells. <i>Nature Communications</i> , 2017, 8, 311.	5.8	35
25	Determination of a Cutoff Time Point for Prophylactic Exchange of Central Venous Catheters for Prevention of Central Venous Catheter-Related Bloodstream Infections in Patients with Hematological Malignancies. <i>Infection Control and Hospital Epidemiology</i> , 2017, 38, 888-889.	1.0	5
26	Biased Low Incidence of Central Venous Catheter-Related Bloodstream Infections in Controlled Clinical Trials?. <i>Infection Control and Hospital Epidemiology</i> , 2016, 37, 617-619.	1.0	3
27	Addition of high-dose cytarabine to immunochemotherapy before autologous stem-cell transplantation in patients aged 65 years or younger with mantle cell lymphoma (MCL Younger): a randomised, open-label, phase 3 trial of the European Mantle Cell Lymphoma Network. <i>Lancet</i> , The, 2016, 388, 565-575.	6.3	328
28	Leukemogenic potency of the novel FLT3-N676K mutant. <i>Annals of Hematology</i> , 2016, 95, 783-791.	0.8	14
29	Characteristics and outcome of patients with primary CNS lymphoma in a "real-life" setting compared to a clinical trial. <i>Annals of Hematology</i> , 2016, 95, 793-799.	0.8	31
30	Internal Tandem Duplication (ITD) in the Tyrosine Kinase Domain of FLT3 Displays Higher Oncogenic Potential in Acute Myeloid Leukemia. <i>Blood</i> , 2016, 128, 5118-5118.	0.6	1
31	Central Venous Catheter-Related Bloodstream Infections in Obese Hematologic Patients. <i>Infection Control and Hospital Epidemiology</i> , 2015, 36, 995-996.	1.0	5
32	Evolutionarily Conserved Signaling Pathways: Acting in the Shadows of Acute Myelogenous Leukemia's Genetic Diversity. <i>Clinical Cancer Research</i> , 2015, 21, 240-248.	3.2	25
33	Very-late-antigen-4 (VLA-4)-mediated brain invasion by neutrophils leads to interactions with microglia, increased ischemic injury and impaired behavior in experimental stroke. <i>Acta Neuropathologica</i> , 2015, 129, 259-277.	3.9	210
34	Results from two phase III studies of bortezomib (BTZ) consolidation vs observation (OBS) post-transplant in patients (pts) with newly diagnosed multiple myeloma (NDMM).. <i>Journal of Clinical Oncology</i> , 2015, 33, 8511-8511.	0.8	9
35	The Novel FLT3-N676K Mutant Induces Acute Leukemia Independently of the Inv(16) Chimeric Gene CBFβ-MYH11. <i>Blood</i> , 2015, 126, 1383-1383.	0.6	0
36	DAPK-HSF1 interaction as a new positive feedback loop for TNF-induced apoptosis in colorectal cancer cells. <i>Journal of Cell Science</i> , 2014, 127, 5273-87.	1.2	20

#	ARTICLE	IF	CITATIONS
37	Clinically relevant doses of FLT3-kinase inhibitors quizartinib and midostaurin do not impair T-cell reactivity and function. <i>Haematologica</i> , 2014, 99, e90-e93.	1.7	14
38	Rapid induction of complete molecular remission by sequential therapy with LDAC and sorafenib in FLT3-ITD-positive patients unfit for intensive treatment: two cases and review of the literature. <i>Journal of Hematology and Oncology</i> , 2013, 6, 39.	6.9	10
39	Sorafenib in Combination With Intensive Chemotherapy in Elderly Patients With Acute Myeloid Leukemia: Results From a Randomized, Placebo-Controlled Trial. <i>Journal of Clinical Oncology</i> , 2013, 31, 3110-3118.	0.8	290
40	Ponatinib may overcome resistance of FLT3-ITD harbouring additional point mutations, notably the previously refractory FLT3-ITD F691I mutation. <i>British Journal of Haematology</i> , 2012, 157, 483-492.	1.2	46
41	3,4-Diarylmaleimides—a novel class of kinase inhibitors—effectively induce apoptosis in FLT3-ITD-dependent cells. <i>Annals of Hematology</i> , 2012, 91, 331-344.	0.8	5
42	Allogeneic Stem Cell Transplantation of Mantle Cell Lymphoma - Results of the Prospective Trials OSHO #060 and OSHO #074. <i>Blood</i> , 2011, 118, 2014-2014.	0.6	0
43	FLT3 as a therapeutic target in AML: still challenging after all these years. <i>Blood</i> , 2010, 116, 5089-5102.	0.6	321
44	Phase IIB Trial of Oral Midostaurin (PKC412), the FMS-Like Tyrosine Kinase 3 Receptor (FLT3) and Multi-Targeted Kinase Inhibitor, in Patients With Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome With Either Wild-Type or Mutated FLT3. <i>Journal of Clinical Oncology</i> , 2010, 28, 4339-4345.	0.8	442
45	Different FLT3-ITD Integration Sites Are Associated with Differential Sensitivity to Tyrosine Kinase Inhibitors (TKI) In Vitro. <i>Blood</i> , 2010, 116, 1709-1709.	0.6	0
46	A Novel Paradigm In Pharmacodynamics of Tyrosine Kinase Inhibitors: Pulse Treatment Induced Apoptosis Is Mediated by Intracellular Retention. <i>Blood</i> , 2010, 116, 1828-1828.	0.6	0
47	A novel molecular mechanism of primary resistance to FLT3-kinase inhibitors in AML. <i>Blood</i> , 2009, 113, 4063-4073.	0.6	106
48	Bis(1H-indol-2-yl)methanones are effective inhibitors of FLT3-ITD tyrosine kinase and partially overcome resistance to PKC412A in vitro. <i>British Journal of Haematology</i> , 2009, 144, 865-874.	1.2	11
49	Identification of a novel type of ITD mutations located in nonjuxtamembrane domains of the FLT3 tyrosine kinase receptor. <i>Blood</i> , 2009, 113, 4074-4077.	0.6	116
50	Insertion of FLT3 internal tandem duplication in the tyrosine kinase domain-1 is associated with resistance to chemotherapy and inferior outcome. <i>Blood</i> , 2009, 114, 2386-2392.	0.6	242
51	The kinase inhibitor LS104 induces apoptosis, enhances cytotoxic effects of chemotherapeutic drugs and is targeting the receptor tyrosine kinase FLT3 in acute myeloid leukemia. <i>Leukemia Research</i> , 2008, 32, 1698-1708.	0.4	24
52	Favorable long-term follow-up results over 6 years for response, survival, and safety with imatinib mesylate therapy in chronic-phase chronic myeloid leukemia after failure of interferon- $\alpha$ treatment. <i>Blood</i> , 2008, 111, 1039-1043.	0.6	195
53	Phase IA/II Study of Oral Panobinostat (LBH589), a Novel Pan- Deacetylase Inhibitor (DACi) Demonstrating Efficacy in Patients with Advanced Hematologic Malignancies. <i>Blood</i> , 2008, 112, 958-958.	0.6	32
54	Prognostic Implication of Insertion of FLT3 Internal Tandem Duplication in the BETA-1-Sheet of the Tyrosine Kinase Domain-1. <i>Blood</i> , 2008, 112, 2514-2514.	0.6	0

#	ARTICLE	IF	CITATIONS
55	Drug treatment is superior to allografting as first-line therapy in chronic myeloid leukemia. <i>Blood</i> , 2007, 109, 4686-4692.	0.6	141
56	Results of a multicenter phase II trial for older patients with c-Kit-positive acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (HR-MDS) using low-dose Ara-C and Imatinib. <i>Cancer</i> , 2007, 109, 907-914.	2.0	51
57	Imatinib combined with mitoxantrone/etoposide and cytarabine is an effective induction therapy for patients with chronic myeloid leukemia in myeloid blast crisis. <i>Cancer</i> , 2007, 109, 1543-1549.	2.0	57
58	The prognosis for patients with chronic myeloid leukemia who have clonal cytogenetic abnormalities in philadelphia chromosome-negative cells. <i>Cancer</i> , 2007, 110, 1509-1519.	2.0	121
59	Clinical resistance to the kinase inhibitor PKC412 in acute myeloid leukemia by mutation of Asn-676 in the FLT3 tyrosine kinase domain. <i>Blood</i> , 2006, 107, 293-300.	0.6	252
60	Five-Year Follow-up of Patients Receiving Imatinib for Chronic Myeloid Leukemia. <i>New England Journal of Medicine</i> , 2006, 355, 2408-2417.	13.9	3,212
61	Identification of a novel activating mutation (Y842C) within the activation loop of FLT3 in patients with acute myeloid leukemia (AML). <i>Blood</i> , 2005, 105, 335-340.	0.6	97
62	AML-associated Flt3 kinase domain mutations show signal transduction differences compared with Flt3 ITD mutations. <i>Blood</i> , 2005, 106, 265-273.	0.6	224
63	Sustained Complete Molecular Remissions After Treatment With Imatinib-Mesylate in Patients With Failure After Allogeneic Stem Cell Transplantation for Chronic Myelogenous Leukemia: Results of a Prospective Phase II Open-Label Multicenter Study. <i>Journal of Clinical Oncology</i> , 2005, 23, 7583-7593.	0.8	89
64	Efficacy and safety of imatinib in adult patients with c-kit-positive acute myeloid leukemia. <i>Blood</i> , 2004, 103, 3644-3654.	0.6	128
65	Imatinib Compared with Interferon and Low-Dose Cytarabine for Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia. <i>New England Journal of Medicine</i> , 2003, 348, 994-1004.	13.9	3,227
66	Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study. <i>Blood</i> , 2002, 99, 1928-1937.	0.6	943
67	Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study. <i>Blood</i> , 2002, 99, 3530-3539.	0.6	1,096
68	A phase 2 study of imatinib in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoid leukemias. <i>Blood</i> , 2002, 100, 1965-1971.	0.6	534
69	Hematologic and Cytogenetic Responses to Imatinib Mesylate in Chronic Myelogenous Leukemia. <i>New England Journal of Medicine</i> , 2002, 346, 645-652.	13.9	1,899